Clinical trials: in Finland
Secondary Lymphedema
Clinical Study With Lymfactin® in the Treatment of Patients With Secondary Lymphedema (AdeLE)
This study evaluates the efficacy of Lymfactin® in patients with secondary lymphedema associated with the treatment of breast cancer by comparing the effects of active study treatment Lymfactin® to placebo.
- Trial name
- AdeLE (NCT03658967)
- Testing
- Lymfactin® (1x10E11 vp)
- Where
- 5 sites in Finland, Sweden
- Volunteers
- 39 people
- Sponsor
- Herantis Pharma Plc.
Dental Crowding
Early Orthodontic Treatment of Dental Crowding
Aim of the study is to compare treatment duration and effects of orthodontic treatment of dental crowding between treatments started at different stages of mixed dentition phase.
- Trial name
- NCT04756843
- Testing
- Quad-helix
- Where
- Finland
- Volunteers
- 60 people
- Sponsor
- University of Helsinki
Small Cell Lung Carcinoma
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)
This study will evaluate the combination of a fixed dose pembrolizumab/vibostolimab co-formulation (MK-7684A) with etoposide/platinum chemotherapy followed by MK-7684A compared to the combination of atezolizumab with…
- Trial name
- NCT05224141
- Testing
- Pembrolizumab/Vibostolimab Co-Formulation, Etoposide, Cisplatin
- Where
- 140 sites in United States, Argentina and 23 more
- Volunteers
- 460 people
- Sponsor
- Merck Sharp & Dohme LLC
Leukemia, Myeloid, Acute
Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission
This study enrolled 472 participants, aged 55 or older, with a diagnosis of de novo acute myeloid leukemia (AML) or AML secondary to prior myelodysplastic disease or chronic myelomonocytic leukemia (CMML), and who have achieved…
- Trial name
- QUAZAR AML-001 (NCT01757535)
- Testing
- Oral Azacitidine
- Where
- 223 sites in United States, Australia and 21 more
- Volunteers
- 472 people
- Sponsor
- Celgene
Blood Pressure, Blood Pressure Measurement
NIBP Cuff Comparison Study
The purpose of the study is to compare NIBP cuff materials and their effect on the measurement results.
- Trial name
- NCT07024472
- Where
- 2 sites in Finland
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Heart Disease
Avoid DeliVering TherApies for Non-sustained Arrhythmias in ICD PatiEnts III
To demonstrate a reduction in the number of ventricular therapies (ATP and Shocks) delivered for treating spontaneous arrhythmia episodes with a fast cycle length (CL≤ 320ms) as a consequence of self-termination and better…
- Trial name
- ADVANCEIII (NCT00617175)
- Testing
- Implantable Defibrillator
- Where
- 91 sites in Belgium, Denmark and 12 more
- Volunteers
- 1,902 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Non-relapsing Secondary Progressive Multiple Sclerosis
Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (HERCULES)
Primary Objective: To determine the efficacy of SAR442168 compared to placebo in delaying disability progression in NRSPMS Secondary Objective: To evaluate efficacy of SAR442168 compared to placebo on clinical endpoints, magnetic…
- Trial name
- HERCULES (NCT04411641)
- Testing
- Tolebrutinib
- Where
- 306 sites in United States, Argentina and 29 more
- Volunteers
- 1,131 people
- Sponsor
- Sanofi
Tachyarrhythmias
SecuraTM ICD Clinical Evaluation Study
The purpose of the Secura clinical study is to evaluate the overall system safety and clinical performance of the Secura DR Implantable Cardioverter Defibrillator (ICD)
- Trial name
- NCT00526227
- Testing
- Secura ICD
- Where
- 13 sites in Austria, Finland and 5 more
- Volunteers
- 81 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Relapsing Multiple Sclerosis
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
Primary Objective: To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated relapse rate (ARR) in participants with relapsing forms of MS Secondary…
- Trial name
- GEMINI 1 (NCT04410978)
- Testing
- Tolebrutinib, Teriflunomide
- Where
- 179 sites in United States, Austria and 22 more
- Volunteers
- 974 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 1
TrialNet Pathway to Prevention of T1D
Rationale: The accrual of data from the laboratory and from epidemiologic and prevention trials has improved the understanding of the etiology and pathogenesis of type 1 diabetes mellitus (T1DM).
- Trial name
- NCT00097292
- Where
- 22 sites in United States, Australia and 4 more
- Volunteers
- 75,000 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Prostate Cancer, Breast Cancer
Measuring Oncological Value of Exercise and Statin
The aim of the study is to find out whether supervised physical exercise during cancer drug treatment improves the effectiveness of the treatment in metastasized breast, kidney, ovarian and prostate cancer compared to…
- Conditions
- Prostate Cancer, Breast Cancer, Kidney Cancer, Ovarian Cancer
- Trial name
- MOVES (NCT05796973)
- Testing
- Guided physical exercise, Atorvastatin, Independent exercise
- Where
- Finland
- Volunteers
- 240 people
- Sponsor
- Tampere University Hospital
Lymphoma
Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas
An open-label, dose escalation and expansion clinical trial to evaluate the safety, tolerability and PK of HMPL-689 in patients with relapsed or refractory lymphomas
- Trial name
- NCT03786926
- Testing
- HMPL-689
- Where
- 27 sites in United States, Finland and 4 more
- Volunteers
- 53 people
- Sponsor
- Hutchmed
Narcolepsy With Cataplexy, Narcolepsy Without Cataplexy
Efficacy and Safety of Pitolisant in Pediatric Narcoleptic Patients With or Without Cataplexy, Double-blind Study Followed by a Prolonged Open-label Period
The purpose of this multicenter double blind study is to assess efficacy and safety of Pitolisant versus placebo in paediatric Narcoleptic patients with or without cataplexy.
- Trial name
- NCT02611687
- Testing
- pitolisant
- Where
- 11 sites in Finland, France and 3 more
- Volunteers
- 110 people
- Sponsor
- Bioprojet
High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This is an international multicenter, open-label, randomized phase III trial including three sequential randomizations to assess efficacy of induction and consolidation chemotherapies and radiotherapy for patients with high-risk…
- Trial name
- HR-NBL2 (NCT04221035)
- Testing
- Vincristine, Carboplatin, Etoposide
- Where
- 142 sites in Australia, Austria and 18 more
- Volunteers
- 800 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Human Papilloma Virus (HPV), Cervical Carcinoma
Transmission of Oncogenic HPV Infection Among Families
The goal of the Transmission of Oncogenic HPV Infection Among Families (TREVINO) study is to improve understanding of how high-risk human papillomavirus (HPV) infections are transmitted within families.
- Conditions
- Human Papilloma Virus (HPV), Cervical Carcinoma, Oropharyngeal Carcinoma, Transmission Vertical
- Trial name
- TREVINO (NCT07036211)
- Where
- 2 sites in Finland
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Tampere University Hospital
Infertility, Female
The Impact of Body Mass Index on the Endometrial Microbiome in IVF Treatments. Tampere Infertility Microbiome Project (TIMP).
This study project is an observational trial involving 90 patients suffering from male type infertility. The patients are divided in two groups (45 patients per group) based on their body mass index (BMI).
- Trial name
- NCT04168567
- Testing
- Microbiome analysis
- Where
- Finland
- Volunteers
- 91 people
- Sponsor
- Tampere University Hospital
Neoplasms, Breast Neoplasms
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
This is a study in adult patients with different types of cancer. The purpose of this study is to find a safe dose of: Xentuzumab in combination with abemaciclib Xentuzumab in combination with abemaciclib and hormonal therapies…
- Trial name
- NCT03099174
- Testing
- Xentuzumab, Abemaciclib, Letrozole
- Where
- 30 sites in United States, Denmark and 5 more
- Volunteers
- 133 people
- Sponsor
- Boehringer Ingelheim
Epithelial Ovarian Cancer, Primary Peritoneal
A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy
This is a Phase 3, randomized, multinational, double-blind, dual placebo-controlled, 4-arm study evaluating rucaparib and nivolumab as maintenance treatment following response to front-line treatment in newly diagnosed ovarian…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Newly Diagnosed
- Trial name
- ATHENA (NCT03522246)
- Testing
- Rucaparib, Nivolumab
- Where
- 238 sites in United States, Australia and 22 more
- Volunteers
- 1,097 people
- Sponsor
- pharmaand GmbH
Multiple Sclerosis
Long-term Extension to Study AC-058B301 to Investigate Safety, Tolerability and Disease Control of Ponesimod 20 mg in Patients With Relapsing Multiple Sclerosis
The study AC-058B301 (OPTIMUM; NCT02425644) has been designed to investigate the efficacy, safety and tolerability of ponesimod in subjects with relapsing multiple sclerosis (RMS).
- Trial name
- OPTIMUM-LT (NCT03232073)
- Testing
- Ponesimod
- Where
- 148 sites in United States, Belarus and 26 more
- Volunteers
- 877 people
- Sponsor
- Actelion
Asthma Bronchiale, Lung Function Tests
Methacholine Challenge Test in School Children With/Without Asthma RISKA
The study includes a pre-study telephone interview with healthy controls to assess their eligibility for participation. During the study visit, a background information form and an asthma questionnaire are completed.
- Conditions
- Asthma Bronchiale, Lung Function Tests, Bronchial Hyperresponsiveness
- Trial name
- RISKA (NCT07031102)
- Where
- Finland
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.